Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, observational, cohort study investigating the efficacy and safety of sofosbuvir and ribavirin in patients with hepatitis C virus in German hepatitis C-registry in real-world setting

Next Previous
Trial Profile

A multi-center, observational, cohort study investigating the efficacy and safety of sofosbuvir and ribavirin in patients with hepatitis C virus in German hepatitis C-registry in real-world setting

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sofosbuvir (Primary) ; Daclatasvir; Ledipasvir/sofosbuvir; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use

Most Recent Events

  • 13 May 2016 New trial record
  • 17 Apr 2016 Results of patients with HCV genotype 2 infection (n=194) presented at The International Liver Congress™ 2016
  • 17 Apr 2016 Subgroup analysis (n=706) of SVR rates of ledipasvir/sofosbuvir treatment for 8-12 weeks until September 2015, in hepatitis C genotype 1 treatment-naive patients were presented at The International Liver Congress™ 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top